<--- Back to Details
First PageDocument Content
Biology / Monoclonal antibodies / Arthritis / Rheumatoid arthritis / Anakinra / Synovial membrane / Joint / Infliximab / Tumor necrosis factor-alpha / Medicine / Anatomy / Immunosuppressants
Date: 2013-02-26 18:00:45
Biology
Monoclonal antibodies
Arthritis
Rheumatoid arthritis
Anakinra
Synovial membrane
Joint
Infliximab
Tumor necrosis factor-alpha
Medicine
Anatomy
Immunosuppressants

Rheumatoid Arthritis PhysioLab® Therapies Adalimumab Infliximab Golimumab

Add to Reading List

Source URL: www.entelos.com

Download Document from Source Website

File Size: 2,02 MB

Share Document on Facebook

Similar Documents

CONTACT: Media: Charlene McGrady, extMDS Pharma Services Scientist to Discuss Development of Biosimilar Monoclonal Antibodies at EGA Symposium

DocID: 1vhgc - View Document

ABIRISK ABIRISK Project Officially Started A growing number of medicines are based on biological molecules such as proteins and monoclonal antibodies. These novel drugs have resulted in new, more effective treatments for

DocID: 1v3WA - View Document

Celartia Protocols Hybridoma Cell culture with Petaka-HOT (High Oxygen Turnover, orange port) Production of Monoclonal Antibodies Petaka-HOT allows culturing non adherent

DocID: 1uTpm - View Document

INTERNSHIP PROPOSAL Institute and Group: IBS group HIV and persistent human viruses Supervisor: Pascal Poignard Email: Research project title: Human monoclonal antibodies: a new therapeutic strategy

DocID: 1uPEI - View Document

Visterra Acquires Exclusive Patent License for Monoclonal Antibodies against Dengue Virus from MIT – Expands Company’s Therapeutic Pipeline for Infectious Diseases – Cambridge, MA – December 2, 2013 – Visterra,

DocID: 1ujGa - View Document